Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand
As a result of the worldwide fight against COVID-19, we have been experiencing higher demand for our goods and services, particularly when it comes to the manufacture of antibiotics. With this, we have had to adapt and make changes to our supply chain processes to alleviate the strain on day-to-day operations.
Since the outbreak of COVID-19, we have seen a delay in both incoming materials and the shipment of our goods. Not only do suppliers now have reduced capacity, but tighter border control restrictions have slowed down the transportation of goods. However, we have been able to adjust to this difficult and testing situation remarkably well ensuring we minimise the impact on the wider supply chain and ultimately patients as much as possible.
The current climate means that the supply of antibiotics is crucial, as secondary bacterial infections are common in the severely ill COVID-19 patients. However, thankfully at Recipharm, we have four dedicated plants that can be used for the manufacturing of these products allowing us to bolster our activity and stay in control of the current demand we are facing.
In addition to this, we have also begun manufacturing the API chloroquine phosphate, for our drug Klorokinfosfat at RPH Pharma. While chloroquine products are not currently approved for the treatment or prevention of COVID-19, some clinical studies involving chloroquine and hydroxychloroquine have recently been initiated making ongoing supply vital.
For more information on how our supply chain has been impacted, read the full article here.